findmyKOL

Terry Davies, MD, FRCP

Basic profile

Endocrinology, Diabetes & Metabolism

ORCIDNPI
RegionNew York, NY · NortheastSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2024Online presenceNot yet checkedPayments2021 onwardNIH funding1985–2025

Terry Davies is an Endocrinology/Metabolic physician. OpenAlex indexes 712 publications with 20,823 citations (h-index 74). By OpenAlex citation count, this profile ranks in the top 10% of Endocrinology, Diabetes & Metabolism profiles in the findmyKOL directory.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
712publications

Distinct works indexed by OpenAlex, matched via ORCID.

20,823citations

Total citations across indexed works.

74h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
4companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
14NIH grants · 1985–2025

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

317 E 17th St
New York, NY 100033804

Telephone

212-420-4412

Registry record last updated 21 Feb 2019.

View the NPPES registry record

Industry payments

4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Hormonal (systemic)

    75.9%
    l-Thyroxine67.2%
    Levothyroxine Sodium73%Synthroid27%
    Part D67 patients
    Thyroid Hormone Synthesis Inhibitor8.7%
    Methimazole100%
    Part D16 patients
  • Metabolism & gastrointestinal

    20.3%
    GLP-1 receptor agonist14.9%
    Ozempic60%Mounjaro41%
    Part D<11 patients
    Biguanide (metformin)5.4%
    Metformin Hcl100%
    Part D<11 patients
  • Cardiovascular

    3.8%
    Statin3.8%
    Rosuvastatin Calcium100%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

14 NIH research awards on record, funded 19852025 per NIH RePORTER. The latest:

103 more award records behind the reveal.Reveal →

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”